Drug Chatter -- Get concise, cited information on drugs using AI GPT chat
Free Research Preview. DrugChatter may produce inaccurate information.

Keytruda patent expiration timeline?

See the DrugPatentWatch profile for Keytruda

When does Keytruda’s patent protection expire?

Keytruda (pembrolizumab) is protected by multiple patents covering different aspects of the drug, including formulation, manufacturing, and specific uses. That means the relevant “expiration timeline” depends on which patent (and which country or region) you mean, and on whether any patent term adjustments or extensions apply. The provided information does not include a specific Keytruda patent list or any dates, so a precise expiration schedule can’t be determined from it alone.

Why different dates show up for “Keytruda patent expiry”

Search results for Keytruda often show different expiration dates because:
- Different patents expire at different times (one set may cover the molecule, others may cover processes or new indications).
- Different jurisdictions (US vs. EU vs. UK, etc.) have different rules for patent terms and data/market exclusivity.
- Exclusivity protections (separate from patents) can extend market protection even after the first patent expires.

Without the underlying patent numbers and jurisdictions, any single “expiration date” would be incomplete.

How long is protection beyond the first patent expiry?

Even if a key patent expires, market entry by competitors can still be constrained by:
- Other still-active patents in the same patent family or covering different claims.
- Regulatory exclusivities that bar certain competing products for a time (depending on local law).

Again, the exact timeline requires the specific patents/exclusivities and their jurisdictions.

What to check to build a real Keytruda expiration timeline

To produce an accurate timeline, you typically need:
- Country/region (e.g., US, EU, UK)
- Patent database entries (patent numbers and assignees)
- Status (granted, expired, terminally disclaimed, etc.)
- Related exclusivity periods (if you’re tracking market entry rather than only patents)

If you tell me the country/region you care about (US or EU, for example) and whether you mean patents only or “when generics/biosimilars can launch,” I can help outline the exact data you’d need to pin down the correct dates.

Sources

No sources were provided in the prompt, so none could be cited.



Other Questions About Keytruda :

when did merck & co first receive approval for keytruda keytruda medication cost in brazile, provide a reference cost which is more effective for killing cancer cells, keytruda or pemetrexed? patente keytruda keytruda wholesale acquisition cost,wac) Who is owns keytruda patent? Are there any keytruda clinical trials for specific cancer types?